Quarterly ResultMay 5, 2026, 07:42 AM
Nuvectis Pharma Q1 Net Loss $6.1M; Cash $25.1M; NXP900 Phase 1b Progress
AI Summary
Nuvectis Pharma reported a net loss of $6.1 million for the first quarter ended March 31, 2026, an increase from $5.3 million in the prior year period. Cash and cash equivalents stood at $25.1 million as of March 31, 2026, a decrease from $31.6 million at year-end 2025. The company highlighted continued patient enrollment in its NXP900 Phase 1b clinical program and presented preclinical data supporting NXP900's use in combination with sotorasib at the 2026 AACR Annual Meeting. A preliminary data readout from the NXP900 Phase 1b study is anticipated in summer 2026.
Key Highlights
- NXP900 Phase 1b clinical program continues patient enrollment in monotherapy and combination arms.
- Preclinical data for NXP900 presented at AACR 2026 supported its use with sotorasib in NSCLC.
- Preliminary data readout from NXP900 Phase 1b study is expected in summer 2026.
- Net loss for Q1 2026 increased to $6.1 million from $5.3 million in Q1 2025.
- Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million on Dec 31, 2025.
- Research and development expenses rose to $4.1 million in Q1 2026 from $3.7 million in Q1 2025.
- General and administrative expenses increased to $2.2 million in Q1 2026 from $1.9 million in Q1 2025.
- Basic and diluted net loss per share was $(0.26) for Q1 2026, compared to $(0.27) in Q1 2025.
Price Impact
More from NVCT